WO2023196958A3 - Tumor and cancer targeting compounds - Google Patents

Tumor and cancer targeting compounds Download PDF

Info

Publication number
WO2023196958A3
WO2023196958A3 PCT/US2023/065508 US2023065508W WO2023196958A3 WO 2023196958 A3 WO2023196958 A3 WO 2023196958A3 US 2023065508 W US2023065508 W US 2023065508W WO 2023196958 A3 WO2023196958 A3 WO 2023196958A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumor
cancer targeting
targeting compounds
compositions
azonafide
Prior art date
Application number
PCT/US2023/065508
Other languages
French (fr)
Other versions
WO2023196958A2 (en
Inventor
Sourav Sinha
Original Assignee
Oncolinx Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolinx Pharmaceuticals filed Critical Oncolinx Pharmaceuticals
Publication of WO2023196958A2 publication Critical patent/WO2023196958A2/en
Publication of WO2023196958A3 publication Critical patent/WO2023196958A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic

Abstract

Described herein are targeted azonafide compositions comprising one or more cytotoxic azonafide-based compounds and methods of using the compositions to deliver a cytotoxic compound to a tumor and/or cancer cell, as well as methods of using the compositions to activate immunogenic cell death (ICD).
PCT/US2023/065508 2022-04-07 2023-04-07 Tumor and cancer targeting compounds WO2023196958A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202263328608P 2022-04-07 2022-04-07
US63/328,608 2022-04-07
US202263386132P 2022-12-05 2022-12-05
US63/386,132 2022-12-05
US202363481525P 2023-01-25 2023-01-25
US63/481,525 2023-01-25

Publications (2)

Publication Number Publication Date
WO2023196958A2 WO2023196958A2 (en) 2023-10-12
WO2023196958A3 true WO2023196958A3 (en) 2023-11-23

Family

ID=88243807

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/065508 WO2023196958A2 (en) 2022-04-07 2023-04-07 Tumor and cancer targeting compounds

Country Status (1)

Country Link
WO (1) WO2023196958A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008316B2 (en) * 2006-09-12 2011-08-30 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Azonafide derived tumor and cancer targeting compounds
US20160067241A1 (en) * 2013-06-13 2016-03-10 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions
US20200030454A1 (en) * 2017-06-23 2020-01-30 VelosBio Inc. ROR1 Antibody Immunoconjugates
WO2022182395A1 (en) * 2021-02-26 2022-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Small molecule inhibitors of stat3 n-terminal domain and methods of use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008316B2 (en) * 2006-09-12 2011-08-30 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Azonafide derived tumor and cancer targeting compounds
US20160067241A1 (en) * 2013-06-13 2016-03-10 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions
US20200030454A1 (en) * 2017-06-23 2020-01-30 VelosBio Inc. ROR1 Antibody Immunoconjugates
WO2022182395A1 (en) * 2021-02-26 2022-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Small molecule inhibitors of stat3 n-terminal domain and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HOWARD: "Investigation Tests Drug to Activate Immune System, Help Fight Cancer", NASA/JOHNSON SPACE CENTER, 15 June 2017 (2017-06-15), XP093114499, Retrieved from the Internet <URL:https://www.sciencedaily.com/releases/2017/06/170615213306.htm#> [retrieved on 20231221] *

Also Published As

Publication number Publication date
WO2023196958A2 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
WO2007038868A3 (en) Novel enediyne compound and uses thereof
WO2003043631A3 (en) Method for identification of tumor targeting enzymes
WO2005040170A8 (en) Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
WO2006066074A3 (en) Lung-targeted drugs
NO20061319L (en) 5-arylpyrimidines as anticancer drugs
WO2007147128A3 (en) Non-toxic anti-cancer drug combining ascorbate, magnesium and a naphthoquinone
WO2021226208A3 (en) Heteroaromatic macrocyclic ether chemotherapeutic agents
WO2020118251A3 (en) Hypoxia targeting compositions and combinations thereof with a parp inhibitor and methods of use thereof
EP1594885B8 (en) Medicament for inhibiting tumour growth
MX2023004937A (en) Solid state forms of substituted pyrazolopyrimidines and uses thereof.
WO2008033891A3 (en) Azonafide derived tumor and cancer targeting compounds
MX2023001788A (en) Cleavable linker compositions and methods.
MX2022002832A (en) Treatment of hr deficient cancer.
WO2023196958A3 (en) Tumor and cancer targeting compounds
AU2002342808A1 (en) Extract with anti-tumor and anti-poisonous activity
WO2023192918A3 (en) Anti-oncogenic phytochemicals and methods and uses for treating cancer
WO2003077874A3 (en) Substituted tetrahydroisoquinoline compounds, methods of making, and their use
WO2019241641A3 (en) Cancer treatment methods
WO2009099959A3 (en) Tumor cell expression of neuropilin as a target for cancer therapy
WO2019006002A8 (en) Methods of treating cancer with small molecule nf-kb inhibitors
MX2022003044A (en) Phospholipid ether conjugates as cancer-targeting drug vehicles.
CR20230413A (en) Modulators of sting (stimulator of interferon genes)
WO2021202830A3 (en) Hsp90-binding conjugates and formulations thereof
WO2022006331A3 (en) Pyridine-1,5-diones exhibitng mnk inhibition and their method of use
WO2004064748A3 (en) Compositions and methods for treatment of ovarian cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23785661

Country of ref document: EP

Kind code of ref document: A2